Found 19 articles for: "Squamous Cell Carcinoma"
Trends in Fluorouracil and Calcipotriene Utilization for Actinic Keratosis
June 2026 | Volume 25 | Issue 6 | Editorials | e56 | Copyright © June 2026
Predicting Benefit of Adjuvant Radiation Therapy for Cutaneous Squamous Cell Carcinoma: A Systematic Review
June 2026 | Volume 25 | Issue 6 | Original Article | 502 | Copyright © June 2026
Background: Cutaneous squamous cell carcinoma (cSCC) is the second most prevalent skin cancer, and its incidence has been rising.Certain patients with high-risk cSCC...
Read MoreEfficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel
May 2026 | Volume 25 | Issue 5 | Original Article | 413 | Copyright © May 2026
Background: Cutaneous squamous cell carcinoma (cSCC) represents a significant clinical challenge in patients with locally advanced (laCSCC) or metastatic (mCSCC) disease who are ...
Read MoreSafety and Efficacy of Aminolevulinic Acid 20% Topical Solution Activated by Blue Light for Facial Cutaneous Squamous Cell Carcinoma in situ
May 2026 | Volume 25 | Issue 5 | Original Article | 454 | Copyright © May 2026
Background: Squamous cell carcinoma in situ (isSCC) is an early-stage cutaneous malignancy that requires effective treatment to prevent progression to invasive SCC. Aminolevulini...
Read MoreEfficacy and Safety of Topical Metformin vs Kligman Formula in the Treatment of Melasma: A Split-Face Study
May 2026 | Volume 25 | Issue 5 | Original Article | 435 | Copyright © May 2026
Background: Melasma is an acquired pigmentary disorder characterized by symmetrical hyperpigmented macules and patches on sun-exposed areas, primarily the face. Kligman's formula...
Read MoreThe Emerging Role of Metformin in Skin Cancer: Mechanistic and Clinical Insights
May 2026 | Volume 25 | Issue 5 | Original Article | 444 | Copyright © May 2026
Background: Metformin, widely used for type 2 diabetes mellitus, has demonstrated antitumor effects through modulation of metabolic and immune pathways. This review explores its ...
Read MoreMalignancy Risk in Autoimmune Blistering Disorders: A Retrospective Cohort Study
May 2026 | Volume 25 | Issue 5 | Editorials | e47 | Copyright © May 2026
Clinical Features and the Management of Drug-Induced Eruptive Keratoacanthoma and Squamous Cell Carcinoma: A Review of 172 Cases
May 2025 | Volume 24 | Issue 5 | Original Article | 476 | Copyright © May 2025
Background: The sudden appearance of keratoacanthomas (KA) and squamous cell carcinomas (SCC) is a serious complication of several oncologic and immunomodulatory medications. The...
Read MoreSquamous Cell Carcinoma In Situ on High-Risk Sites and With Larger Sizes Require More Stages for Clearance With Mohs Surgery
May 2025 | Volume 24 | Issue 5 | Original Article | 494 | Copyright © May 2025
Background: Few studies have evaluated Mohs micrographic surgery (MMS) for the treatment of squamous cell carcinoma in situ or evaluated the results by Mohs Appropriate Use Crite...
Read MoreSynergistic Mechanisms of 5-Fluorouracil and Imiquimod in the Treatment of Actinic Keratoses
May 2025 | Volume 24 | Issue 5 | Editorials | e35 | Copyright © May 2025
Citation: Regester RM, Cannella AC, Thiele GM, et al. Synergistic mechanisms of 5-fluorouracil and imiquimod in the treatment of actinic keratoses. J Drugs Dermatol. 2025;24(5):e35....
Read MoreIncorporating a Prognostic Gene Expression Profile Test into the Management of Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel Report
February 2024 | Volume 23 | Issue 2 | Original Article | 54 | Copyright © February 2024
Background: Cutaneous squamous cell carcinoma (cSCC) is a growing health concern with a rapidly increasing incidence. Disease-specific mortality is typically preceded by a m...
Read MoreEruptive Squamous Cell Carcinomas Following Treatment With Fludarabine and Discussion of Treatment
May 2023 | Volume 22 | Issue 5 | Case Reports | 509 | Copyright © May 2023
Shah M, Wald J, Hanke CW. Eruptive Squamous cell carcinomas following treatment with fludarabine and discussion of treatment. J Drugs Dermatol. 2023;22(5):509-510....
Read MoreDilute Intralesional 5-Fluorouracil for the Treatment of Squamous Cell Carcinomas and Keratoacanthomas: A Case Series
May 2023 | Volume 22 | Issue 5 | Case Reports | 507 | Copyright © May 2023
Background: Intralesional 5-fluorouracil (5-FU) is a promising, yet sparsely studied alternative to surgical treatment for nonmelanoma skin cancer (NMSC).1 Previous studies of in...
Read MoreNon-Invasive Diagnosis of Sun Damaged Skin: Actinic Keratosis Vs Squamous Cell Carcinoma
May 2023 | Volume 22 | Issue 5 | Original Article | 440 | Copyright © May 2023
Importance: Actinic keratosis (AK) is a premalignant lesion that has a1% to 10% potential of progression to squamous cell carcinoma (SCC), but it is not possible to determine whi...
Read MoreTreatment of Reactive Keratoacanthomas with Acitretin Following Multiple Excisions and Mohs Surgery for Recurrent Squamous Cell Carcinoma
December 2022 | Volume 21 | Issue 12 | Case Reports | 1353 | Copyright © December 2022
Surgical intervention is seen as the gold standard in the treatment of Squamous cell carcinoma. Yet, in cases of recurrence, repeated surgical procedures may unwittingly foment the rise of reactive ke...
Read MoreSafety and Efficacy of TGF-β1/COX-2 Silencing Therapeutic in Adults With Cutaneous Squamous Cell Carcinoma In Situ
May 2022 | Volume 21 | Issue 5 | Original Article | 472 | Copyright © May 2022
This single-center, open label, dose escalation cohort study evaluated the safety and efficacy of various doses of intralesional injections of TGF-Read More
Dermoscopy and Reflectance Confocal Microscopy in Actinic Keratosis, Intraepithelial Carcinoma, and Invasive Squamous Cell Carcinoma
March 2022 | Volume 21 | Issue 3 | Original Article | 259 | Copyright © March 2022
Background: Patients with multiple actinic keratosis (AK), have pre-neosplastic abnormalities, constituting the sites of new tumors, this region is called the cancerization field. Due...
Read MoreCombining Panitumumab With Anti-PD-1 Antibody in Cutaneous Squamous Cell Carcinoma of the Head and Neck After Inadequate Response to Anti-PD-1 Antibody Alone
August 2021 | Volume 20 | Issue 8 | Case Reports | 901 | Copyright © August 2021
Anti-epidermal growth factor receptor (EGFR) antibodies and anti-programmed cell death 1 protein (PD-1) antibodies have been used separately to treat metastatic cutaneous squamous cell carcinoma (cSCC...
Read MoreRapid Evolution of a Squamous Cell Carcinoma In Situ to Locally Invasive With Perineural Involvement
November 2020 | Volume 19 | Issue 11 | Case Reports | 1110 | Copyright © November 2020
We present a case of rapidly progressing squamous cell carcinoma in situ (SCCis) with progression to aggressive SCC. An elderly gentleman with multiple medical comorbidities presented with a left zygo...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
